Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines ...

A team led by UT Southwestern Medical Center researchers has uncovered a molecular pathway that links obesity to widespread ...

By reinforcing exercise, health care providers can ensure that GLP-1 therapy leads to weight loss, sustains muscle mass, and ...

Heather Gay exclusively tells Us Weekly why GLP-1s are central to her plan to maintain her weight loss alongside Atkins ...

This executive summary provides an overview of the 2025 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, which is organized around the Utstein ...

Novo Nordisk today announced that its weight-loss drug, Wegovy (semaglutide 2.4mg), is now officially available in Malaysia, ...

Today, the compounded GLP-1 market is in upheaval. The FDA has banned copies of GLP-1 weight loss drugs, and a number of ...

The buyout is a bet by Lilly on an increasingly popular drug target known as NLRP3 inflammasomes, which are implicated in an ...

Arkansas state laws that create an income tax credit for businesses that relocate their corporate headquarters in Arkansas and require coverage of treatment and conditions caused by severe obesity are ...

The U.S. Food and Drug Administration (FDA) has approved its first oral glucagon-like peptide (GLP)-1 pill for weight management, a news release from Novo Nordisk announced on Monday. The pill, Wegovy ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making history again with the first FDA approval of a GLP-1 pill for weight loss.

Some experts believe that anyone could benefit from GLP-1 medications, as the popular drugs have become more widespread and accessible. Others, however, warn that the decision to take the diabetes and ...